[PDF][PDF] Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute …
D Cilloni, A Renneville, F Hermitte… - Journal of Clinical …, 2009 - researchgate.net
D Cilloni, A Renneville, F Hermitte, RK Hills, S Daly, JV Jovanovic, E Gottardi, M Fava…
Journal of Clinical Oncology, 2009•researchgate.netPurpose Risk stratification in acute myeloid leukemia (AML) is currently based on
pretreatment characteristics. It remains to be established whether relapse risk can be better
predicted through assessment of minimal residual disease (MRD). One proposed marker is
the Wilms tumor gene WT1, which is overexpressed in most patients with AML, thus
providing a putative target for immunotherapy, although in the absence of a standardized
assay, its utility for MRD monitoring remains controversial.
pretreatment characteristics. It remains to be established whether relapse risk can be better
predicted through assessment of minimal residual disease (MRD). One proposed marker is
the Wilms tumor gene WT1, which is overexpressed in most patients with AML, thus
providing a putative target for immunotherapy, although in the absence of a standardized
assay, its utility for MRD monitoring remains controversial.
Purpose
Risk stratification in acute myeloid leukemia (AML) is currently based on pretreatment characteristics. It remains to be established whether relapse risk can be better predicted through assessment of minimal residual disease (MRD). One proposed marker is the Wilms tumor gene WT1, which is overexpressed in most patients with AML, thus providing a putative target for immunotherapy, although in the absence of a standardized assay, its utility for MRD monitoring remains controversial.
researchgate.net